Interest of flexible videocystoscopy in blue light (+Hexvix ®) in consultation for the diagnosis of vesical tumor;Intérêt de la vidéocystoscopie souple en lumière bleue (+Hexvix®) en consultation pour le diagnostic des tumeurs de vessie

Progres en Urologie

Volumn 22, Issue 3, 2012, Pages 172-177

  Bertrand, J ^a   Soustelle, L ^a   Gres P ^a   Wagner, L ^a   Muyshondt, C ^a   Boukaram, M ^a   Ben Naoum, K ^a   Costa, P ^a   Droupy, S ^a  

^a NÎMES UNIVERSITY HOSPITAL   (France)

Author keywords

Consultation; Hexaminolevulinate; Vesical tumor; Vesical videofibroscopy

Indexed keywords

5-AMINOLEVULINIC ACID HEXYL ESTER; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; DIAGNOSTIC AGENT; DRUG DERIVATIVE;

AGED; ARTICLE; BLADDER TUMOR; COMPARATIVE STUDY; CYSTOSCOPY; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; VIDEORECORDING;

AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; CYSTOSCOPY; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS; VIDEO RECORDING;

EID: 84857453563     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2011.09.012     Document Type: Article

References (13)

1. Pfister C., Roupret M., Wallerand H., Davin J.L., Quintens H., Guy L., et al. Recommandations en onco-urologie: tumeurs urothéliales. Prog Urol 2010, 20(Suppl. 4):S203-S340.
2. SobinLH, Wittekind C. TNM classification of malignant tumours 2002, John Wiley, New Jersey. 6th ed.
3. HAS. Commission de la transparence, avis, Hexvix 85mg, poudre et solvant pour solution pour administration intravésicale B/1, CIP: 369 497-7, 28 février 2007.
4. Costly tests may not help detect bladder cancer recurrence, M.D. Anderson Study Finds, University of Texas, M.D. Anderson News Release 03/03/10.
5. Jichlinski P., Guillou L., Karlsen S.J., et al. Hexyl aminolevulinate fluorescence cystoscopy: a new diagnostic tool for the photodiagnosis of superficial bladder cancer: a multicentre study. J Urol 2003, 170:226-229.
6. Jocham D., et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005, 174:862-866.
7. Jacqmin D., Bordier B., Guillotreau J. Hexaminolevulinate fluorescence cystoscopy in 2009. Prog Urol 2010, 20(Suppl. 1):S50-S53.
8. Witjes J.A., Moonen P.M., van der Heijden A.G. Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective Phase II study. Eur Urol 2005, 47(3):319-322. [Epub 2005 Jan 1].
9. Schmidbauer J., et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004, 171:135-138.
10. ®) des tumeurs urothéliales de vessie: étude préliminaire. Prog Urol 2010, 20(9):644-650. [Epub 2010 Jun 8].
11. Fradet Y., Grossman H.B., Gomella L., Lerner S., Cookson M., Albala D., et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007, 178(1):68-73. [discussion 73. Epub 2007 May 11].
12. Abascal Junquera J.M., Hevia Suárez M., Abascal García J.M., Estébanez C., Astudillo A., Abascal R. Initial experience in the diagnosis and treatment of superficial bladder tumors with Hexvix. Arch Esp Urol 2008, 61(4):475-482. [discussion 482-3. Spanish].
13. Sievert K.D., Amend B., Nagele U., Schilling D., Bedke J., Horstmann M., et al. Economic aspects of bladder cancer: what are the benefits and costs?. World J Urol 2009, 27(3):295-300. [Epub Review].